glp-1 sarcopenia The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition Sarcopenia‐related changes in serum GLP‐1

Cost is a significant issue, one physician said

GLP-1s often work better for both goals

The federal multidistrict litigation is moving forward, and new Ozempic lawsuits continue being filed

The danger of muscle loss during weight loss

Use for acute episodes only

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists Source In both trials, after 72 weeks of treatment, patients who received Zepbound at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of patients who received Zepbound achieved at least 5% weight reduction compared to placebo